NETRAMARK HOLDINGS INC.

Ajouter à une liste

Communiqués NetraMark Holdings Inc. Canadian Securities Exchange

Actions

AIAI

CA64119M1059

Logiciels

Cours en clôture Canadian Securities Exchange Autres places de cotation 20/02/2026			Varia. 5j.	Varia. 1 janv.
1,070 ^CAD	-.--%		-3,77%	-7,27%

14/05	NetraMark Holdings Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 31 mars 2026	CI
07/05	NetraMark Holdings Inc. annonce la démission de Lawrence Guy de son poste d'administrateur, effective au 7 mai 2026	CI

Communiqués

09/06	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026	AQ
25/05	Upcoming Meeting Dates - May 25, 2026	NE
20/05	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting	AQ
14/05	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum	AQ
07/05	NetraMark Announces Change To Board Of Directors	AQ
05/05	NetraMark Holdings Inc. (AIAI) ouvre les marchés	NE
05/05	NetraMark Holdings Inc. (AIAI) Opens the Market	NE
04/05	NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI	AQ
30/04	NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026	AQ
22/04	NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs	AQ
20/04	Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development	AQ
09/04	Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain	AQ
25/03	NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset	AQ
19/03	NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference	AQ
11/03	NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Espace mes listes

Palmarès

Suite du Palmarès

Palmarès

Suite du Palmarès

Devises / Forex

Matières Premières

Cryptomonnaies

Taux d'Intérêts

DERNIÈRES HEURES | -40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !

PROFITEZ-EN MAINTENANT